CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $230.98M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
320.22BKRW230.98M · vs all stocks (USD)
Revenue (TTM)
0.00KRWvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.7690xvs all stocks
52-Week Change
-50.59%vs all stocks
Market Capitalization
320.22BKRW230.98M · vs all stocks (USD)
Enterprise Value
304.55BKRW219.68M · vs all stocks (USD)
Price to Book (MRQ)
4.42xvs Biotechnology peers
Enterprise to EBITDA
-10.47xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-16.04%vs Biotechnology peers
Return on Equity (TTM)
-101.11%vs Biotechnology peers
Revenue (TTM)
0.00KRWvs all stocks (USD)
Gross Profit (TTM)
-2.68BKRW-1.94M · vs all stocks (USD)
EBITDA (TTM)
-29.08BKRW-20.98M · vs all stocks (USD)
Net Income (TTM)
-51.51BKRW-37.16M · vs all stocks (USD)
Operating Cash Flow (TTM)
-30.00BKRW-21.64M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-41.07BKRW-29.63M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Operating Income
-36.29BKRW-26.18M · vs all stocks (USD)
Pre-tax Income
-46.31BKRWFY2025 · Dec 31, 2025Net Income
-46.31BKRWFY2025 · Dec 31, 2025EBIT
-41.76BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-29.47BKRWFY2025 · Dec 31, 2025Research & Development
31.25BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
1.04BKRWFY2025 · Dec 31, 2025Other Operating Expenses
204.89MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
457.72MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
4.54BKRWFY2025 · Dec 31, 2025EPS (Basic)
-3.23KKRWFY2025 · Dec 31, 2025EPS (Diluted)
-3.23KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
14.33MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
14.33MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-46.31BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-42.20BKRWFY2025 · Dec 31, 2025Free Cash Flow
-42.50BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
10.16BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-46.31BKRWFY2025 · Dec 31, 2025Stock-based Compensation
953.87MKRWFY2025 · Dec 31, 2025Other Non-cash Items
4.09BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-41.02MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-895.30MKRWFY2025 · Dec 31, 2025Capital Expenditures
-300.68MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.90BKRWFY2025 · Dec 31, 2025Purchase of Investments
-55.49BKRWFY2025 · Dec 31, 2025Sale of Investments
48.29BKRWFY2025 · Dec 31, 2025Other Investing Activity
207.20MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-7.29BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
43.00BKRWFY2025 · Dec 31, 2025Other Financing Charges
56.84MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
45.34BKRWFY2025 · Dec 31, 2025Shares Outstanding
15.18MSharesUpdated Sep 21, 2026Float Shares
9.85MSharesUpdated Sep 21, 2026% Held by Insiders
37.17%vs all stocks
% Held by Institutions
7.74%vs all stocks
Total Cash (MRQ)
82.70BKRW59.65M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.43KKRWUpdated Sep 21, 2026Total Debt (MRQ)
60.35BKRW43.53M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.8322xvs Biotechnology peers
Current Ratio (MRQ)
1.82xvs Biotechnology peers
Book Value per Share (MRQ)
4.77KKRWUpdated Sep 21, 2026Total Assets
109.72BKRW79.14M · vs all stocks (USD)
Total Current Assets
32.34BKRWFY2025 · Dec 31, 2025Total Liabilities
104.70BKRWFY2025 · Dec 31, 2025Total Non-current Assets
77.38BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
7.68BKRWFY2025 · Dec 31, 2025Total Current Liabilities
97.01BKRWFY2025 · Dec 31, 2025Cash Equivalents
10.16BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
10.16BKRWFY2025 · Dec 31, 2025Other Short-term Investments
14.00BKRWFY2025 · Dec 31, 2025Inventory
1.68BKRWFY2025 · Dec 31, 2025Short-term Debt
55.32BKRWFY2025 · Dec 31, 2025Other Current Liabilities
890.00KRWFY2025 · Dec 31, 2025Long-term Debt
1.36BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-190.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
7.22BKRWFY2025 · Dec 31, 2025Retained Earnings
-245.32BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
5.03BKRW3.62M · vs all stocks (USD)
52-Week Low
20.65KKRWUpdated Sep 21, 202652-Week High
66.00KKRWUpdated Sep 21, 202652-Week Change
-50.59%vs all stocks
Beta
0.7690xvs all stocks
50-Day MA
24.16KKRWUpdated Sep 21, 2026200-Day MA
40.23KKRWUpdated Sep 21, 2026Avg 10-Day Volume
20.36KSharesUpdated Sep 21, 2026Avg 30-Day Volume
23.21KSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-3.23KKRWUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $230.98M, lower than 95% of all stocks globallySignificant
Market cap (USD): 230,984,647.013Global P5: 275,556,405.438
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Keros Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shenqi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Sionna Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Samyang Biopharmaceuticals Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Niagen Bioscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking